Items tagged with Drug-resistant TB
Deaths rates declined in South Africa due to HIV success – report (post)
Death rates have declined, largely due to successes in HIV, but a lot more needs to be done to defeat its “terrible twin”, tuberculosis (TB).
Drug-resistant TB a major concern in Ghana (post)
Ghanaian experts are concerned about the rising number of tuberculosis. The Ghana Health Service said 14,632 people were diagnosed with TB and put on treatment in 2015.
Otsuka and Mylan announce license agreement to commercialize delamanid (Deltyba™) for MDR-TB in high-burden countries (post)
TOKYO, HERTFORDSHIRE, England and PITTSBURGH, Aug. 24, 2017 -- Otsuka Pharmaceutical Co. Ltd. (Otsuka) and Mylan N.V. (NASDAQ, TASE: MYL) have entered into a license agreement between their respective subsidiaries, Otsuka Novel Products GmbH (ONPG) and Mylan Pharmaceuticals Private Limited (Mylan), to commercialize delamanid for the treatment of adults with pulmonary multidrug-resistant tuberculosis (MDR-TB) in low- and middle-income countries. Delamanid was discovered and developed, and is currently marketed by Otsuka under the brand name Deltyba™.
NIH funds SLU research of possible treatment for drug-resistant TB (post)
Saint Louis University is leading a multi-national clinical trial of what could become a regimen for drug resistant tuberculosis (TB) that does not require injectable medications. The project is funded by a $6.4 million task order from the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH).
Evaluation of a nurse practitioner-physician task-sharing model for multidrug-resistant TB in South Africa (post)
Abstract
Six-month response to delamanid treatment in MDR-TB patients (post)
Abstract
Off-label use of bedaquiline in children and adolescents with multidrug-resistant TB (post)
Abstract
We describe 27 children and adolescents <18 years of age who received bedaquiline during treatment for multidrug-resistant tuberculosis. We report good treatment responses and no cessation attributable to adverse effects. Bedaquiline could be considered for use with this age group for multidrug-resistant tuberculosis when treatment options are limited.
Decentralized care for multidrug-resistant TB: a systematic review and meta-analysis (post)
Abstract
Nationwide programme to test all TB patients in India (post)
Beginning this month, health authorities will commence a nationwide programme to test every tuberculosis (TB) patient for signs of resistance to first-line drugs.
Prevention of hearing loss in patients with multidrug-resistant TB (post)
A correspondence published in The Lancet addresses the issue of prevention of hearing loss in patients with multidrug-resistant TB by using newer drugs bedaquiline or delamanid, and repurposed drugs linezolid and clofazimine, instead of an injectable agent.
Page 45 of 117 · Total posts: 0
←First 44 45 46 Last→